Telix Pharmaceuticals (TLX) Total Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $517.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 28.06% to $517.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $517.0 million through Dec 2025, up 28.06% year-over-year, with the annual reading at $517.0 million for FY2025, 35.21% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $517.0 million at Telix Pharmaceuticals, up from $403.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $517.0 million in Q4 2025, with the low at $59.9 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $326.9 million, with a median of $403.7 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities surged 574.17% in 2024, then rose 28.06% in 2025.
  • Over 3 years, Total Non-Current Liabilities stood at $59.9 million in 2023, then soared by 574.17% to $403.7 million in 2024, then grew by 28.06% to $517.0 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $517.0 million, $403.7 million, and $59.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.